Table 2.
Overview of the characteristics of the identified RCTs by PROM category
| Questionnaires | EQ-5D-3L index | HUI | OHS | OKS | PDQ | QLQ-C30 | SF-12 | SF-36 | Overall |
|---|---|---|---|---|---|---|---|---|---|
| Number of studies | 72 | 13 | 4 | 9 | 17 | 21 | 25 | 76 | 237 |
| Years included | 2013 | 2009–2013 | 2009–2013 | 2009–2013 | 2009–2013 | 2013 | 2013 | 2013 | 2009–2013 |
| Studies using PROM as a primary outcome (%) | 38.9 | 69.2 | 25.0 | 44.4 | 41.2 | 23.8 | 24.0 | 26.3 | 33.8 |
| Size of studiesa | |||||||||
| Median | 329 | 255 | 155 | 165 | 294 | 309 | 241 | 202 | 251 |
| IQR | 190–600 | 139,622 | n/a | 120–200 | 184–359 | 178–420 | 195–392 | 138–304 | 159–416 |
| Range | 100–18,624 | 104–762 | 126–161 | 100–1715 | 109–586 | 108–1528 | 116–1573 | 100–3.057 | 100–18,624 |
| Follow-up data is measured repeatedly (opposed to once only) (%) | 87.5 | 92.3 | 50.0 | 88.9 | 76.47 | 81.0 | 84.0 | 77.6 | 82.3 |
| Length of follow-up to primary assessment time point (in months) | |||||||||
| Median | 12 | 12 | 18 | 12 | 6 | 12 | 9 | 15 | 12 |
| IQR | 6–17 | 10.5–22 | 7.5–36 | 12–24 | 4–10.5 | 6–12 | 6–15 | 4–12 | 6–15 |
| Range | 1–60 | 6–36 | 3–48 | 3–60 | 3–36 | 0.25–78 | 1.5–24 | 0.75–60 | 0.25–78 |
aThe size of the studies described here refers to the number of participants randomised to the two relevant treatment arms considered in this review